FDA grants accelerated approval to Breyanzi (lisocabtagene maraleucel) for follicular lymphoma (Catapult’s regulatory round-up – May 2024)
On 15 May 2024, the FDA granted accelerated approval to lisocabtagene maraleucel for adults with relapsed or refractory follicular lymphoma (FL) who have received two or more prior lines of systemic therapy. Please find further information here.
Published on the 5th of June in Catapult’s regulatory round-up for May 2024.
OpenEdition vous propose de citer ce billet de la manière suivante :
adelage (4 novembre 2024). FDA grants accelerated approval to Breyanzi (lisocabtagene maraleucel) for follicular lymphoma (Catapult’s regulatory round-up – May 2024). ELSIBI. Consulté le 16 janvier 2025 à l’adresse https://doi.org/10.58079/12m75
